Skip to main content

LAVA Therapeutics NV

LVTXDelisted Nov 21, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001840748

LAVA Therapeutics NV was delisted on Nov 21, 2025; its insiders filed their last Form 4 on Nov 17, 2025; 21 institutions reported holding it in 13F filings for Q3 2025, worth $16.1M in total; no superinvestor held it.

13F holders, Q3 2021

Institutional positions in LAVA Therapeutics NV as of Sep 30, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
19
+1 vs. Q2 2021
Shares held
8.22M
−555.1K (−6.3%) vs. Q2 2021
Total value
$48.6M
−$46.8M (−49.0%) vs. Q2 2021
New holders
6
2 more added
Sold out
5
6 more reduced

Compare with Q2 2021: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting LVTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ3 2021: 19 institutions
Q1 2021: 24 institutionsQ2 2021: 18 institutionsQ3 2021: 19 institutionsQ4 2021: 20 institutionsQ1 2022: 18 institutionsQ2 2022: 17 institutionsQ3 2022: 13 institutionsQ4 2022: 20 institutionsQ1 2023: 19 institutionsQ2 2023: 15 institutionsQ3 2023: 14 institutionsQ4 2023: 14 institutionsQ1 2024: 20 institutionsQ2 2024: 19 institutionsQ3 2024: 21 institutionsQ4 2024: 22 institutionsQ1 2025: 20 institutionsQ2 2025: 19 institutionsQ3 2025: 21 institutionsQ4 2025: 0 institutionsQ1 2026: 0 institutionsQ2 2026: 0 institutions
Value heldQ3 2021: $48.6M
Q1 2021: $139.1MQ2 2021: $95.5MQ3 2021: $48.6MQ4 2021: $44.3MQ1 2022: $35.2MQ2 2022: $22.8MQ3 2022: $34.1MQ4 2022: $26.3MQ1 2023: $11.2MQ2 2023: $11.7MQ3 2023: $8.47MQ4 2023: $9.22MQ1 2024: $12.5MQ2 2024: $6.77MQ3 2024: $5.99MQ4 2024: $6.15MQ1 2025: $10.2MQ2 2025: $10.6MQ3 2025: $16.1MQ4 2025: $0Q1 2026: $0Q2 2026: $0
Institutions holding LVTX and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20260$0
Q4 20250$0
Q3 202521$16.1M
Q2 202519$10.6M
Q1 202520$10.2M
Q4 202422$6.15M
Q3 202421$5.99M
Q2 202419$6.77M
Q1 202420$12.5M
Q4 202314$9.22M
Q3 202314$8.47M
Q2 202315$11.7M
Q1 202319$11.2M
Q4 202220$26.3M
Q3 202213$34.1M
Q2 202217$22.8M
Q1 202218$35.2M
Q4 202120$44.3M
Q3 202119$48.6M
Q2 202118$95.5M
Q1 202124$139.1M

Institutions, Q3 2021

Shares, value and share of portfolio for each institution holding LAVA Therapeutics NV; share changes are against Q2 2021.

Institutions holding LVTX in Q3 2021
InstitutionSharesValue% of portfolioChange in sharesAction
Novo Holdings A/S3,327,312$19.7M1.02%00.0%Unchanged
Redmile Group, LLC2,816,196$16.7M0.29%00.0%Unchanged
Nicholas Investment Partners, LP528,953$3.13M0.23%−252,914−32.3%Reduced
Nantahala Capital Management, LLC369,290$2.19M0.13%−11,937−3.1%Reduced
AXA S.A.229,121$1.36M0.00%+8,458+3.8%Added
Sphera Funds Management Ltd.215,359$1.27M0.13%00.0%Unchanged
Artal Group S.A.200,000$1.18M0.03%00.0%Unchanged
Falcon Edge Capital, LP140,229$830.0K0.06%−4,673−3.2%Reduced
DAFNA Capital Management LLC139,332$825.0K0.22%+3,700+2.7%Added
Point72 Asset Management, L.P.123,911$734.0K0.00%+123,911New
Millennium Management LLC71,833$425.0K0.00%−66,998−48.3%Reduced
Boothbay Fund Management, LLC18,358$109.0K0.00%+18,358New
Bank of New York Mellon Corp17,647$104.0K0.00%−7,641−30.2%Reduced
Geode Capital Management, LLC10,086$59.0K0.00%−2,911−22.4%Reduced
Bank of America Corp9,070$54.0K0.00%+9,070New
Point72 Hong Kong Ltd631$4.00K0.00%+631New
TSFG, LLC400$2.00K0.00%00.0%Unchanged
Cubist Systematic Strategies, LLC101$1.00K0.00%+101New
Advisor Group Holdings, Inc.48$00.00%+48New
Wellington Management Group LLP0$00.00%−203,800−100.0%Sold out
Woodline Partners LP0$00.00%−86,904−100.0%Sold out
Citadel Advisors LLC0$00.00%−61,874−100.0%Sold out
New York State Common Retirement Fund0$00.00%−19,136−100.0%Sold out
Tower Research Capital LLC (TRC)0$00.00%−557−100.0%Sold out